Canaccord lowered the firm’s price target on Atara Biotherapeutics to $13 from $19 and keeps a Buy rating on the shares. The firm said Atara announced the EMBOLD Phase 2 in Progressive MS did not meet its primary endpoint. Atara will now focus on tab-cel’s BLA submission expected in 2Q24.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ATRA: